In Advance Of Pharma Partnership, Intarcia Inks Equity Deal With Quintiles
This article was originally published in The Pink Sheet Daily
Executive Summary
The CRO will conduct Phase III trials on an implantable device that delivers exenatide to Type 2 diabetes patients, while an anticipated pharma partner will help commercialize it around the world.